

## Title Breast Cancer Treatments

---

Reference Number: RDF1624-23

Date of Response: 11/07/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Therapy	Patients – total - Treated
Abemaciclib + Aromatase Inhibitor* or Fulvestrant	*<5
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	*<5
Capecitabine as a single agent	18
Eribulin as a single agent or in combination	12
Everolimus + Exemestane	*<5
Fulvestrant as a single agent	0
TK Inhibitors (Neratinib/Lapatinib)	0
Parp Inhibitors (Olaparib/Talazoparib)	*<5
Palbociclib + Aromatase Inhibitor* or Fulvestrant	67
Pembrolizumab	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	*<5
Ribociclib + Aromatase Inhibitor* or Fulvestrant	39
Sacituzumab Govitecan	7
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	52
Taxane and/or Anthracycline in combination	0
Trastuzumab as a single agent or in combination	92
Trastuzumab conjugates (Trastuzumab emtansine, Trastuzumab deruxtecan)	10
Any other active systemic anti-cancer therapy	241

Q2. Does your trust participate in any clinical trials for the treatment of breast cancer.  
Yes.

If so, please provide the name of each trial and the number of patients taking part.

Trial name	Recruits
ARTemis	*<5
ATNEC	5
CANDO-3	*<5
CONCEPT	8
DS8201-A-U301, Phase 3, HER2-Positive Breast cancer	*<5
EndoNET	*<5
FAST-Forward	128
GLACIER	23
IMPORT HIGH	5
LORIS	11
MAMMO-50	24
APHINITY	8
KATHERINE	*<5
Persephone	14
plasmaMATCH	66
POETIC	84
POETIC-A	6
POSNOC	14
PRIME II	10
SUPREMO	8
TACT2	40
The MARECA study	9

**\*<5 - section 40:**

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and **should not be published**.